Table 3.
Prevalence of antibodies against a selection of specific neutrophil antigens in PSC patients
| Antibody | Frequency range % (median) | No. of patients range (median) | Number of studies |
| Anti-lactoferrin | 4-50 (29) | 12-76 (24) | 10[55,57,84,85,87,88,99,102,137,144] |
| Anti-myeloperoxidase | 0-33 (2) | 12-73 (40) | 7[57,78,84,85,87,99,102] |
| Anti-BPI | 5-46 (29) | 36-76 (69) | 5[55,57,59,78,99] |
| Anti-cathepsin G | 0-35 (21) | 14-76 (55) | 5[55,57,84,87,99] |
| Anti-proteinase 3 | 0-44 (4) | 25-73 (62) | 5[57,78,87,99,102] |
| Anti-elastase | 0-35 (9) | 23-76 (69) | 4[55,87,99,102] |
| Anti-α-enolase | 11-33 (27) | 15-55 (36) | 3[57,89,147] |
| Anti-catalase | 16-60 (38) | 15-55 (35) | 2[57,89] |
| Anti-α-antigen | 33 (33) | 12 (12) | 1[85] |
| Anti-h-lamp-2 | 71 (71) | 73 (73) | 1[78] |
| Anti-TBB51 |
PSC: Primary sclerosing cholangitis; Anti-BPI: Antibodies against bactericidal/permeability increasing protein; Anti-h-lamp-2: Antibodies against human lysosomal-associated membrane protein 2; Anti-TBB5: Antibodies against Tubulin beta-5 chain.
1
No prevalence studies published.